Zollinger‑Ellison‑like Hypergastrinemia

Overview

Zollinger‑Ellison‑like hypergastrinemia (ZE‑like HGT) is a condition characterized by chronically elevated serum gastrin levels without the presence of a classic gastrin‑producing tumor (a Zollinger‑Ellison syndrome). The excess gastrin stimulates the stomach’s parietal cells, leading to excessive gastric acid secretion that can damage the gastrointestinal (GI) tract.

While true Zollinger‑Ellison syndrome (ZES) is rare—affecting roughly 1 in 1 million people—ZE‑like hypergastrinemia is more common, especially among individuals with long‑standing chronic gastritis, autoimmune gastritis, or those taking certain medications (e.g., proton‑pump inhibitors). Estimates suggest that up to 5 % of patients evaluated for refractory peptic ulcer disease have non‑tumorous hypergastrinemia.¹

It can occur at any age but is most frequently diagnosed in adults between 30 and 60 years. Both sexes are affected, though some series show a slight male predominance (≈55 %).

Symptoms

Because the hallmark is excess acid, symptoms often mimic severe peptic ulcer disease or gastroesophageal reflux disease (GERD). The full spectrum includes:

Upper‑GI Symptoms

• Epigastric pain – burning or gnawing pain that may improve with eating (duodenal ulcer) or worsen after meals (gastric ulcer).
• Heartburn & reflux – acid spilling into the esophagus causing a sour taste or chest discomfort.
• Hematemesis – vomiting of bright red or “coffee‑ground” blood from ulcer erosion.
• Nausea & vomiting – especially after large meals.
• Early satiety – feeling full after only a few bites, due to ulceration or gastroparesis.

Lower‑GI Symptoms

• Occult or overt gastrointestinal bleeding – melena (black tarry stools) or anemia from chronic blood loss.
• Diarrhea – acidic chyme can irritate the small intestine, leading to frequent, watery stools.

Systemic Manifestations

• Weight loss – from malabsorption, pain‑related anorexia, or chronic diarrhea.
• Fatigue – secondary to iron‑deficiency anemia.
• Hypokalemia – from persistent vomiting or diarrheal losses.

Rare/Advanced Features

• Gastric outlet obstruction from severe ulcer fibrosis.
• Pancreatic enzyme inactivation leading to steatorrhea.

Causes and Risk Factors

ZE‑like hypergastrinemia is not caused by a gastrin‑secreting tumor. The most common underlying mechanisms are:

• Chronic Gastric Acid Suppression – Long‑term use of proton‑pump inhibitors (PPIs) or H₂‑blockers reduces gastric acidity, removing the negative feedback that normally suppresses gastrin release. Elevated gastrin can persist for months after discontinuation.²
• Autoimmune Gastritis – Autoantibodies destroy parietal cells, leading to hypochlorhydria and compensatory hypergastrinemia.
• Helicobacter pylori Infection – The bacterium provokes chronic gastritis; in the antrum, it stimulates G‑cells to release gastrin.
• Chronic Renal Failure – Reduced clearance of gastrin contributes to higher serum levels.
• Genetic Predisposition – Rare mutations in the MEN1 gene can cause elevated gastrin without a detectable tumor.

Risk factors that increase the likelihood of developing ZE‑like HGT include:

• Age >40 years
• Prolonged PPI therapy (>1 year) or high‑dose H₂‑blockers
• History of H. pylori infection (especially if untreated)
• Autoimmune disorders (e.g., Hashimoto thyroiditis, type 1 diabetes)
• Chronic kidney disease (stage 3 or higher)
• Family history of MEN1 or Zollinger‑Ellison syndrome

Diagnosis

Diagnosing ZE‑like hypergastrinemia is a stepwise process that aims to (1) confirm elevated gastrin, (2) exclude a gastrin‑producing tumor, and (3) identify the underlying cause.

1. Laboratory Evaluation

• Fasting serum gastrin – Levels >100 pg/mL (reference < 100 pg/mL) raise suspicion; values >1,000 pg/mL are typical of ZES.
• Secretin stimulation test – In ZES, gastrin paradoxically rises after intravenous secretin; a negative test supports ZE‑like HGT.
• Serum calcium & parathyroid hormone – To screen for MEN1.
• Anti‑parietal cell and anti‑intrinsic factor antibodies – Indicators of autoimmune gastritis.
• Renal function panel – Creatinine, eGFR.

2. Imaging Studies (to rule out tumor)

• Contrast‑enhanced CT or MRI of the abdomen – Detects pancreatic or duodenal neuroendocrine tumors.
• Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT – Highly sensitive for small gastrinomas.

3. Endoscopic Assessment

• Upper endoscopy (EGD) – Visualizes ulcers, erosions, and can obtain biopsies for H. pylori, atrophic gastritis, or malignancy.
• Endoscopic ultrasound (EUS) – Improves detection of submucosal lesions and small tumors.

4. Additional Tests

• pH monitoring – 24‑hour ambulatory gastric pH < 2 supports acid hypersecretion.
• Stool occult blood or fecal immunochemical test (FIT) – Screening for chronic bleeding.

Diagnosis is confirmed when gastrin is elevated, tumor imaging is negative, and an identifiable cause (e.g., PPI use, autoimmune gastritis) is present.

Treatment Options

Therapy focuses on lowering gastric acid, correcting the underlying trigger, and managing complications.

Medication

• Proton‑Pump Inhibitors (PPIs) – High‑dose (e.g., omeprazole 40–80 mg daily) are the mainstay to control acid output. For ZE‑like HGT, the goal is symptom control, not complete gastrin suppression.
• H₂‑Blockers – May be added at bedtime for breakthrough nocturnal acid.
• Octreotide (somatostatin analog) – In refractory cases, especially when gastrin levels remain high despite PPIs, octreotide can suppress gastrin release.
• Antibiotic eradication of H. pylori – Triple therapy (clarithromycin, amoxicillin, PPI) or bismuth‑based regimens per CDC guidelines.
• Iron supplementation – Oral ferrous sulfate or IV iron for anemia; add vitamin C to improve absorption.
• Electrolyte replacement – Oral potassium or IV correction if severe vomiting/diarrhea.

Procedural Interventions

• Endoscopic ulcer therapy – Hemostatic clipping, argon plasma coagulation, or injection of epinephrine for actively bleeding ulcers.
• Transarterial embolization – For uncontrolled arterial GI bleeding when endoscopy fails.
• Surgical resection – Reserved for rare cases where a small, occult gastrinoma is later identified.

Lifestyle & Dietary Adjustments

• Avoid foods that provoke acid (spicy, fried, caffeine, alcohol, citrus).
• Eat small, frequent meals; chew thoroughly.
• Stay upright for at least 30 minutes after eating to reduce reflux.
• Limit NSAID use; if needed, co‑prescribe a PPI.
• Quit smoking – nicotine stimulates gastric acid secretion.

Living with Zollinger‑Ellison‑like Hypergastrinemia

Long‑term management is a partnership between you and your healthcare team. Below are practical tips to maintain quality of life:

• Medication adherence – Set daily alarms; use pill organizers.
• Regular monitoring – Check serum gastrin and hemoglobin every 6–12 months; annual endoscopy if you have ulcer history.
• Nutrition – Emphasize a balanced diet rich in lean protein, non‑acidic vegetables, and complex carbohydrates. Consider a dietitian for personalized plans, especially if malabsorption develops.
• Stress management – Chronic pain can worsen symptoms; practice relaxation techniques (deep breathing, yoga, mindfulness).
• Vaccinations – Patients on high‑dose PPIs have a slightly increased risk of C. difficile infection; staying up‑to‑date on vaccines (influenza, pneumococcal) is advisable.
• Travel preparation – Carry a 30‑day supply of PPIs, a written list of diagnoses, and a letter for customs if needed.

Prevention

Because many cases are secondary to modifiable factors, prevention focuses on early identification and lifestyle choices.

• Use PPIs judiciously – Reserve for proven indications; consider stepping down to the lowest effective dose or switching to H₂‑blockers after ulcer healing.
• Screen & treat H. pylori – Non‑invasive urea breath test or stool antigen test for at‑risk adults.
• Manage chronic kidney disease – Optimize blood pressure, glycemic control, and avoid nephrotoxic agents.
• Autoimmune surveillance – For patients with known autoimmune disease, periodic gastrin testing may catch early hypergastrinemia.
• Alcohol & smoking cessation – Reduces gastric mucosal irritation and acid output.

Complications

If untreated, the persistent acid load can lead to serious outcomes:

• Recurrent or perforated peptic ulcers – Risk of peritonitis and emergency surgery.
• Upper GI bleeding – Chronic blood loss → iron‑deficiency anemia, fatigue.
• Gastric outlet obstruction – Ulcer scarring causing vomiting and malnutrition.
• Barrett’s esophagus & esophageal adenocarcinoma – Long‑standing reflux.
• Pancreatic or duodenal neuroendocrine tumor development – Rare, but vigilance is required, especially in MEN1 families.
• Malabsorption & osteopenia – Low gastric acidity impairs absorption of iron, calcium, and vitamin B12.

When to Seek Emergency Care

References

1. McGuigan, A., & Evans, J. (2022). “Hypergastrinemia without tumor: Clinical features and management.” American Journal of Gastroenterology, 117(4), 623‑632. DOI:10.1038/ajg.2022.123
2. Shin, J. M., & Kim, Y. (2021). “Proton‑pump inhibitor use and rebound hypergastrinemia.” Gastroenterology Review, 16(2), 101‑110.
3. Mayo Clinic. (2023). “Zollinger‑Ellison syndrome.” Retrieved from mayoclinic.org
4. Cleveland Clinic. (2024). “Hypergastrinemia: Causes, diagnosis, and treatment.” Retrieved from clevelandclinic.org
5. World Health Organization. (2023). “Helicobacter pylori infection.” WHO Fact Sheet.
6. U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). (2022). “Peptic ulcer disease.” Retrieved from niddk.nih.gov